Equities analysts expect Aphria Inc (NYSE:APHA) to post earnings of ($0.01) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Aphria’s earnings, with the highest EPS estimate coming in at $0.01 and the lowest estimate coming in at ($0.02). Aphria posted earnings per share of ($0.15) in the same quarter last year, which would indicate a positive year over year growth rate of 93.3%. The firm is scheduled to announce its next quarterly earnings report on Monday, April 20th.
On average, analysts expect that Aphria will report full-year earnings of $0.03 per share for the current financial year, with EPS estimates ranging from ($0.11) to $0.10. For the next fiscal year, analysts anticipate that the firm will post earnings of $0.11 per share, with EPS estimates ranging from ($0.07) to $0.30. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that follow Aphria.
Aphria (NYSE:APHA) last released its quarterly earnings data on Tuesday, October 15th. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.10. The company had revenue of $126.10 million for the quarter, compared to analysts’ expectations of $131.15 million. Aphria’s revenue for the quarter was up 848.1% compared to the same quarter last year.
APHA has been the subject of several recent research reports. Jefferies Financial Group set a $8.30 target price on shares of Aphria and gave the company a “buy” rating in a research report on Tuesday, October 15th. CIBC upgraded shares of Aphria from an “underperform” rating to a “neutral” rating and set a $7.00 target price for the company in a research report on Tuesday. ValuEngine lowered shares of Aphria from a “buy” rating to a “hold” rating in a research report on Thursday, December 5th. Bank of America initiated coverage on shares of Aphria in a research report on Monday. They set a “neutral” rating for the company. Finally, Pi Financial set a $9.00 target price on shares of Aphria and gave the company a “buy” rating in a research report on Tuesday, October 15th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $12.09.
NYSE APHA traded up $0.02 during trading hours on Friday, hitting $5.26. 284,892 shares of the company’s stock traded hands, compared to its average volume of 5,287,557. The business’s fifty day moving average price is $4.95 and its two-hundred day moving average price is $5.61. The firm has a market capitalization of $1.26 billion, a P/E ratio of -47.87, a P/E/G ratio of 5.22 and a beta of 2.78. Aphria has a 52 week low of $3.76 and a 52 week high of $10.95.
Several institutional investors and hedge funds have recently bought and sold shares of APHA. ETF Managers Group LLC bought a new position in shares of Aphria in the second quarter worth approximately $48,941,000. Jefferies Group LLC boosted its position in shares of Aphria by 449.7% in the second quarter. Jefferies Group LLC now owns 323,900 shares of the company’s stock worth $2,273,000 after purchasing an additional 416,516 shares during the period. Bank of America Corp DE boosted its position in shares of Aphria by 410.2% in the second quarter. Bank of America Corp DE now owns 507,034 shares of the company’s stock worth $3,554,000 after purchasing an additional 407,658 shares during the period. Renaissance Technologies LLC bought a new position in shares of Aphria in the second quarter worth approximately $1,700,000. Finally, Scotia Capital Inc. boosted its position in shares of Aphria by 870.4% in the second quarter. Scotia Capital Inc. now owns 201,066 shares of the company’s stock worth $1,410,000 after purchasing an additional 180,347 shares during the period. Institutional investors and hedge funds own 9.60% of the company’s stock.
Aphria Company Profile
Aphria Inc produces and sells medical cannabis in Canada and internationally. The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It serves patients and health professionals. The company also sells its products online. Aphria Inc is headquartered in Leamington, Canada.
Featured Story: Cash Flow
Get a free copy of the Zacks research report on Aphria (APHA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aphria Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aphria and related companies with MarketBeat.com's FREE daily email newsletter.